Biography
Executive level leadership with extensive experience in drug development, clinical science, translational medicine and overseeing development strategies for early to late stage assets. Initiation and execution on Academic Alliances and Partnerships. Known for versatility and unique ability to extend skills across diverse functional roles, including strategic planning, product development, brand strategies, ability to develop trusted relationships with both internal and external partners, exceptional medical and scientific knowledge with a broad understanding of disease entities and corresponding molecular and business implications.
Emerging Therapeutics Showcase:
3TBiosciences
T cell receptor-based therapeutics company against novel targets for cancer and other immune-related diseases. The platform combines high diversity libraries and active machine learning to discover novel tumor-specific targets and assess the specificity and cross-reactivity of a potential TCR therapeutic.
Identification of Novel pHLA Targets for Solid Tumor
The PMWC 2022 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.
- Emerging Therapeutics/Cell Therapy
- Emerging Therapeutics/CVD
- Emerging Therapeutics/Gene Therapy
- Emerging Therapeutics/Immunotherapy
- Emerging Therapeutics/Radiation Therapy